- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06711887
Estudio de extensión de fase III sobre la eficacia y seguridad de Ianalumab con o sin retirada del tratamiento del estudio en participantes con nefritis lúpica (extensión SIRIUS-LN) (SIRIUS-LN ext)
Un estudio de extensión de etiqueta abierta para evaluar la eficacia y seguridad de Ianalumab con o sin retirada del tratamiento del estudio en participantes adultos con nefritis lúpica que completaron el tratamiento del estudio en el estudio principal CVAY736K12301 (extensión SIRIUS-LN)
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety
- after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
- of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
Descripción general del estudio
Descripción detallada
The SIRIUS-LN extension study is an up to 6-year open-label extension study for participants who have completed the treatment periods (blinded Treatment Period-1 and blinded Treatment Period-2) of the SIRIUS-LN core study on double-blind or open-label study treatment.
Investigators will use their clinical judgment to decide if it is beneficial for participants to continue with the extension study. In this extension study participants who achieve CRR or PRR status at Week 140 will be withdrawn from study treatment and will maintain the SoC medication as required. These up to 6 additional years in the extension study will allow to measure sustained remission, flares and safety off-study treatment. However, in the event of renal flares during the extension study, these participants who withdraw study treatment will have the option to receive open-label ianalumab.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Acceso ampliado
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Novartis Pharmaceuticals
- Número de teléfono: 1-888-669-6682
- Correo electrónico: novartis.email@novartis.com
Copia de seguridad de contactos de estudio
- Nombre: Novartis Pharmaceuticals
- Número de teléfono: +41613241111
- Correo electrónico: novartis.email@novartis.com
Ubicaciones de estudio
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasil, 29055-450
- Reclutamiento
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40150-150
- Reclutamiento
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-221
- Reclutamiento
- Novartis Investigative Site
-
-
Pernambuco
-
Recife, Pernambuco, Brasil, 50740-900
- Reclutamiento
- Novartis Investigative Site
-
-
São Paulo
-
Santo André, São Paulo, Brasil, 09090-790
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Olomouc, Chequia, 779 00
- Activo, no reclutando
- Novartis Investigative Site
-
Prague, Chequia, 128 00
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Reclutamiento
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Seoul, Corea del Sur, 06591
- Reclutamiento
- Novartis Investigative Site
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Novartis Investigative Site
-
Seoul, Corea del Sur, 04763
- Reclutamiento
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Corea del Sur, 16499
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
New York
-
Orchard Park, New York, Estados Unidos, 14127
- Reclutamiento
- Circuit Clinical
-
Investigador principal:
- Isha Gupta
-
Contacto:
- Gabriella Demelo
- Correo electrónico: gdemelo@circuitclinical.com
-
-
-
-
-
Grenoble, Francia, 38043
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Reclutamiento
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01011
- Reclutamiento
- Novartis Investigative Site
-
-
Departamento de Quetzaltenango
-
Quetzaltenango, Departamento de Quetzaltenango, Guatemala, 09001
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Tuenmen, Hong Kong, 999077
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungría, 1097
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malasia, 50586
- Reclutamiento
- Novartis Investigative Site
-
-
Sarawak
-
Sibu, Sarawak, Malasia, 96000
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, México, 68020
- Reclutamiento
- Novartis Investigative Site
-
Querétaro, México, 76070
- Reclutamiento
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, México, 37160
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Beijing, Porcelana, 100034
- Reclutamiento
- Novartis Investigative Site
-
Chongqing, Porcelana, 400038
- Reclutamiento
- Novartis Investigative Site
-
Guangzhou, Porcelana, 510280
- Reclutamiento
- Novartis Investigative Site
-
Guangzhou, Porcelana, 510080
- Reclutamiento
- Novartis Investigative Site
-
Shanghai, Porcelana, 200080
- Reclutamiento
- Novartis Investigative Site
-
Shanghai, Porcelana, 200040
- Reclutamiento
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510000
- Reclutamiento
- Novartis Investigative Site
-
Shantou, Guangdong, Porcelana, 515000
- Activo, no reclutando
- Novartis Investigative Site
-
Shenzhen, Guangdong, Porcelana, 518037
- Reclutamiento
- Novartis Investigative Site
-
-
Guangxi
-
Liuzhou, Guangxi, Porcelana, 545005
- Reclutamiento
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430060
- Reclutamiento
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Porcelana, 130041
- Reclutamiento
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, Porcelana, 110004
- Reclutamiento
- Novartis Investigative Site
-
-
Shandong
-
Binzhou, Shandong, Porcelana, 256603
- Reclutamiento
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Porcelana, 315016
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Bucharest, Rumania, 022328
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapur, 169608
- Reclutamiento
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, Singapur, 308433
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- Reclutamiento
- Novartis Investigative Site
-
Bangkok, Tailandia, 10330
- Reclutamiento
- Novartis Investigative Site
-
Bangkok, Tailandia, 10700
- Reclutamiento
- Novartis Investigative Site
-
Chiang Mai, Tailandia, 50200
- Reclutamiento
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Tailandia, 90110
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
-
Taichung, Taiwán, 40447
- Reclutamiento
- Novartis Investigative Site
-
-
-
-
VNM
-
Ho Chi Minh City, VNM, Vietnam, 700000
- Reclutamiento
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed informed consent prior to participation in the extension study.
- Participants must have participated in the SIRIUS-LN core study and must have completed the entire treatment up to Week 144 on double-blind or open label study treatment.
Exclusion Criteria:
- Use of prohibited therapies
- Pregnant or nursing (lactating) women.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Study Treatment Withdrawal (cohort 1)
(Cohort 1): Study Treatment-Withdrawal group. Participants who received blinded study treatment in the core study and achieve CRR or PRR at Week 140 in the core study will enter the extension study and discontinue study treatment while maintaining standard of care (SoC) medication, as required. If renal flare criteria are met, participants will be eligible to receive open-label ianalumab. |
|
|
Experimental: Open-Label Ianalumab (cohort 2)
(Cohort 2): Open-Label Ianalumab group: Participants who received blinded study treatment throughout the core study and did not achieve CRR or PRR at Week 140 of the core study, or who had switched to open-label ianalumab during the core study, will be eligible or will continue to receive open-label ianalumab in the extension study. |
Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohort 1: Time to renal flare, increase in immunosuppressive medication, or death
Periodo de tiempo: Between Week 144E1 and EOS (up to Week 456)
|
Cohort 1: To estimate the time to renal flare, increase in immunosuppressive medication, or death following study treatment withdrawal in participants who completed the SIRIUS-LN core study on double-blind treatment and achieved CRR or PRR at Week 140 of the core study |
Between Week 144E1 and EOS (up to Week 456)
|
|
Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohort 2: Incidence and titer of anti-ianalumab antibodies in serum (ADA assay)
Periodo de tiempo: from Week 144E1 up to Week 456
|
To assess immunogenicity to ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 2: Ianalumab concentration in serum using a validated ELISA
Periodo de tiempo: from Week 144E1 up to Week 456
|
To assess pharmacokinetics of ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Glomerulonefritis
- Lupus Eritematoso Sistémico
- Nefritis
- Enfermedades de la piel y del tejido conectivo
- Nefritis lúpica
- Ianalumab
Otros números de identificación del estudio
- CVAY736K12301E1
- 2024-515280-60-00 (Otro identificador: EU CTR)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .